Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Mild Cognitive Impairment Clinical Trials

22 recruiting trials for Mild Cognitive Impairment. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
22
Total Trials
22
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGEarly Phase 1NCT06538311

Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in...

Sponsor: Massachusetts General HospitalEnrolling: 301 location
RECRUITINGPhase 1NCT06548191

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology...

Sponsor: University of California, San DiegoEnrolling: 601 location
RECRUITINGNCT06335836

The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD...

The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1. To...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 2091 location
RECRUITINGNCT05887674

Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease

This study is a multicentre, randomized, double-blind, controlled trial that aims to investigate the efficacy of multi-domain life-style intervention including low...

Sponsor: Ruijin HospitalEnrolling: 1801 location
RECRUITINGNCT06733714

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation...

BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological...

Sponsor: Universidade Federal do Rio de JaneiroEnrolling: 401 location
RECRUITINGNCT04124029

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

This is a research study that aims to examine whether Veterans with mild Traumatic Brain Injuries are at risk for dementia by studying their memory, brain wave activity, brain...

Sponsor: VA Office of Research and DevelopmentEnrolling: 8001 location
RECRUITINGNCT06561906

Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic,...

To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment...

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEnrolling: 10001 location
RECRUITINGNCT07402356

VR Pupillometry in Cognitive Impairment

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective,...

Sponsor: Max-Planck-Institute of PsychiatryEnrolling: 1401 location
RECRUITINGNCT03472664

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults...

Sponsor: Wake Forest University Health SciencesEnrolling: 1201 location
RECRUITINGNCT06040905

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia)...

The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and...

Sponsor: Chung Shan Medical UniversityEnrolling: 1001 location
RECRUITINGNCT03954899

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of...

Sponsor: Natalie DenburgEnrolling: 2301 location
RECRUITINGNCT03025334

tDCS on Parkinson's Disease Cognition

Parkinson's disease (PD) has been classically regarded as a "movement disorder", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life...

Sponsor: University of ManitobaEnrolling: 361 location
RECRUITINGNCT07441915

Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training

People with Parkinson's disease are at higher risk of cognitive decline, and current treatments cannot fully prevent this. This study explores non-drug ways to support brain...

Sponsor: University of ZurichEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT03836950

rTMS to Improve Cognition in Parkinson's

The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS),...

Sponsor: VA Office of Research and DevelopmentEnrolling: 562 locations
RECRUITINGPhase 2NCT04643327

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in...

Sponsor: The University of QueenslandEnrolling: 281 location
RECRUITINGNCT03174938

The Swedish BioFINDER 2 Study

The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to...

Sponsor: Skane University HospitalEnrolling: 29502 locations
RECRUITINGNCT03233646

Retinal Imaging in Neurodegenerative Disease

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus...

Sponsor: Duke UniversityEnrolling: 20001 location
RECRUITINGPhase 1NCT04396873

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain...

Sponsor: National Institute of Mental Health (NIMH)Enrolling: 1841 location
RECRUITINGNCT06897670

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared...

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional...

Sponsor: Mayo ClinicEnrolling: 2001 location
RECRUITINGNCT06089096

Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment

Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation...

Sponsor: The University of Hong KongEnrolling: 2501 location
RECRUITINGNCT06150352

Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment

Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation...

Sponsor: The University of Hong KongEnrolling: 1801 location
RECRUITINGNCT03761381

OCT Angiography and NRAI in Dementia

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in...

Sponsor: Oregon Health and Science UniversityEnrolling: 201 location

Frequently Asked Questions

There are currently 22 clinical trials for Mild Cognitive Impairment, with 22 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Mild Cognitive Impairment, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Mild Cognitive Impairment, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.